cabiralizumab   Click here for help

GtoPdb Ligand ID: 9107

Synonyms: BMS-986227 | FPA-008 | FPA008
Immunopharmacology Ligand
Compound class: Antibody
Comment: Cabiralizumab is an investigational humanized monoclonal antibody targeting the receptor tyrosine kinase, CSF1R (Fms). It is being investigated for its potential anti-cancer activity.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with peptides claimed in patent US20110274683 [1]
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Cabiralizumab (research code FPA008) is in early stage clinical trials for solid tumours and rheumatoid arthritis (RA). Click here to link to all FPA008 trials registered with ClinicalTrials.gov. Immuno-oncology trials are evaluating cabiralizumab monotherapy and combination with the immune checkpoint inhibitor nivolumab, anti-PD-1 mAb., in selected advanced solid tumours (Phase 1).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Anti-CSF1R antibodies prevent binding of the receptor's endogenous ligand CSF1 (or M-CSF). This action reduces monocyte infiltration into tumours and inhibits the acumulation of tumour-associated macrophages (TAMs). In RA anti-CSF1R antibodies are expected to reduce pro-inflammatory macrophage activity (and possibly osteoclast activity), to improve disease symptoms.